Literature DB >> 18006760

Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma.

Hiroshi Aoki1, Tomohisa Yokoyama, Keishi Fujiwara, Ana M Tari, Raymond Sawaya, Dima Suki, Kenneth R Hess, Kenneth D Aldape, Seiji Kondo, Rakesh Kumar, Yasuko Kondo.   

Abstract

PURPOSE: Glioblastoma is the most common primary malignant tumor in the brain. It aggressively invades the surrounding parenchyma, often allowing the tumor to progress after surgery. Accumulating evidence has shown that phosphorylated p21-activated kinase 1 (Pak1), a mediator of small guanosine triphosphatases, plays a role in the proliferation, survival, and invasiveness of cancer cells. Thus, we examined patterns of Pak1 expression in glioblastoma and sought to determine whether the level of phosphorylated Pak1 in glioblastoma cells is associated with patient survival time. EXPERIMENTAL
DESIGN: We carried out immunohistochemical staining for phosphorylated Pak1 in tumor specimens from 136 patients with glioblastoma; the tumors were classified according to Pak1 protein levels in the cytoplasm and nucleus. We compared the patients' overall survival times using Kaplan-Meier analysis and estimated the effects of levels of cytoplasmic or nuclear phosphorylated Pak1. We then down-regulated Pak1 by using small interfering RNA to knock down Pak1 in two glioblastoma cell lines to determine whether Pak1 contributed to cell viability and invasion.
RESULTS: Median overall survival was significantly shorter in patients with tumors showing a moderate or high level of cytoplasmic phosphorylated Pak1 than in patients with tumors showing no cytoplasmic phosphorylated Pak1. The level of nuclear phosphorylated Pak1 was not related to survival time. Knockdown of Pak1 suppressed the invasion, but not the viability, of U87-MG and U373-MG cells.
CONCLUSIONS: The presence of phosphorylated Pak1 in the cytoplasm of glioblastoma cells is associated with shorter survival, and Pak1 plays a role in the invasiveness of glioblastoma. These data suggest that Pak1 might be a potential target for the management of glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006760     DOI: 10.1158/1078-0432.CCR-07-0145

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

1.  ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration.

Authors:  Liangping Yuan; Mariarita Santi; Elisabeth J Rushing; Robert Cornelison; Tobey J MacDonald
Journal:  Clin Exp Metastasis       Date:  2010-06-06       Impact factor: 5.150

Review 2.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

3.  MiR-1261/circ-PTPRZ1/PAK1 pathway regulates glioma cell growth and invasion.

Authors:  Feng Zhang; Shu-Rong Mai; Fei-Peng Cao; Can-Xian Cao; Liang Zhang
Journal:  Hum Cell       Date:  2019-07-30       Impact factor: 4.174

Review 4.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

5.  Interrogation of kinase genetic interactions provides a global view of PAK1-mediated signal transduction pathways.

Authors:  Jae-Hong Kim; Yeojin Seo; Myungjin Jo; Hyejin Jeon; Young-Seop Kim; Eun-Jung Kim; Donggun Seo; Won-Ha Lee; Sang Ryong Kim; Nozomu Yachie; Quan Zhong; Marc Vidal; Frederick P Roth; Kyoungho Suk
Journal:  J Biol Chem       Date:  2020-10-15       Impact factor: 5.157

Review 6.  MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells.

Authors:  Jeffrey V Brower; Paul A Clark; Will Lyon; John S Kuo
Journal:  Neurochem Int       Date:  2014-06-14       Impact factor: 3.921

7.  A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.

Authors:  Zhi Sheng; Li Li; Lihua J Zhu; Thomas W Smith; Andrea Demers; Alonzo H Ross; Richard P Moser; Michael R Green
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

8.  Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.

Authors:  Justin Sharim; Randy Tashjian; Nima Golzy; Nader Pouratian
Journal:  J Clin Neurosci       Date:  2016-03-09       Impact factor: 1.961

9.  MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions.

Authors:  Sirigiri Divijendra Natha Reddy; Kazufumi Ohshiro; Suresh K Rayala; Rakesh Kumar
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

10.  LncRNA and mRNA expression profiles of glioblastoma multiforme (GBM) reveal the potential roles of lncRNAs in GBM pathogenesis.

Authors:  Qi Li; Hongmei Jia; Haowen Li; Chengya Dong; Yajie Wang; Zhongmei Zou
Journal:  Tumour Biol       Date:  2016-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.